


Eslicarbazepine acetate

Cat. No.:	HY-B0703
CAS No.:	236395-14-5
Molecular Formula:	C ₁₇ H ₁₆ N ₂ O ₃
Molecular Weight:	296.32
Target:	Beta-secretase; Sodium Channel
Pathway:	Neuronal Signaling; Membrane Transporter/Ion Channel
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (337.47 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		3.3747 mL	16.8736 mL	33.7473 mL
	5 mM		0.6749 mL	3.3747 mL	6.7495 mL
	10 mM		0.3375 mL	1.6874 mL	3.3747 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Eslicarbazepine acetate (BIA 2-093), an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.

In Vivo

Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which

could theoretically improve tolerability^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sibhghatulla Shaikh, et al. Aptiom (Eslucarbazepine Acetate) as a Dual Inhibitor of β -Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA